CSC. G. Schaar

C. G. Schaar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


C. G. Schaar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long‐term complete remission in IgD‐myeloma

    by R. H. H. Bemelmans, D. W. van Toorn, L. van Leeuwen, C. G. Schaar

    Abstract:  Long‐term complete remission in IgD multiple myeloma (MM) is rare. This case report describes a patient with a stage IIIB IgD‐MM, who was treated with conventional melphalan and prednisone chemotherapy. The monoclonal protein disappeared after four cycles and therapy was discontinued after 14 cycles. Re‐evaluation after a follow up of more than 8 years demonstrates a continuing complete remission suggesting a cure. This is remarkable, considering that several adverse prognostic factors were present. In addition a concise review on IgD‐MM is given.


  • Open Access

    Interferon-α as maintenance therapy in patients with multiple myeloma

    by C. G. Schaar, H. C. Kluin-Nelemans, C. Te Marvelde, S. le Cessie, W. P. Breed, W. E. Fibbe, W. A. van Deijk, M. M. Fickers, K. J. Roozendaal, P. W. Wijermans

    Background: The effect of interferon-α 2b (IFN-α-2b) on progression-free and overall survival as well as quality of life (QoL) was studied in mainly elderly patients with multiple myeloma (MM), who reached a plateau phase after melphalan/prednisone induction. Patients and methods: In an open phase III trial, 262 patients, median age 69 years (range 34–91), received at least 10 monthly courses of melphalan/prednisone followed by response evaluation. Plateau phase was reached by 128 patients. Next, 90 patients were randomized between IFN-α-2b and no maintenance therapy. Reasons for non-randomization were: refusal (18), concomitant disease (nine), protocol violation (six), WHO performance status >2 (four) and allogeneic transplantation (one) Results: At a median follow-up from diagnosis of 97 months (0–140) for those patients alive, IFN-α-2b therapy was associated with improved progression-free survival (median 13.5 versus 8.4 months from randomization), although this did not translate in a better overall survival (41 versus 38.4 months). One-third of patients discontinued IFN-α due to toxicity. No differences were observed between patient groups in QoL. Conclusions: IFN maintenance therapy in MM prolongs progression-free survival and, provided that the burden of toxicity is not too high, does not adversely affect QoL.


  • Open Access

    Early response to therapy and survival in multiple myeloma

    by C. G. Schaar, J. C. Kluin‐Nelemans, S. le Cessie, P. F. H. Franck, M. C. Te Marvelde, P. W. Wijermans

    Summary: Whether the response to chemotherapy is a prognosticator in multiple myeloma (MM) is still not known. Therefore, the relationship between survival and the rate of monoclonal protein (M‐protein) decrement during the first cycles of therapy was prospectively assessed in 262 patients with newly diagnosed MM that were included in a phase III trial (HOVON‐16). M‐proteins were collected monthly during melphalan–prednisone therapy (MP: melphalan 0·25 mg/kg, prednisone 1·0 mg/kg orally for 5 d every 4 weeks). Patients with light chain disease (n = 18), immunoglobulin M (IgM)‐MM (n = 1) and no immunotyping (n = 1) were excluded. Of the 242 patients studied, 75% had IgG M‐protein and 25% IgA; MM stages: I: 1%, II: 35% and III: 64%. The median M‐protein decrease after the first cycle of MP was 21% for IgG and 27% for IgA, and declined to < 5% after four cycles. An obvious survival advantage was seen for patients who had an M‐protein decrease of at least 30% after the first MP cycle, which became significant when an M‐protein decrease of 40% or more was reached. As established prognostic parameters (Salmon & Durie stage, serum creatinine, and haemoglobin) also remained prognostically significant, we concluded that early response to MP predicts for survival in MM.


  • The Classification of Plasma Cell Dyscrasias: Alternatives to the Durie & Salmon Diagnostic System

    by F. Ong, J. Hermans, E. M. Noordijk, C. G. Schaar, J. C. Kluin-Nelemans

    • 11 July 1998
      • Vol. 142  (28) , 1591-5

    [The risk of a multiple myeloma in patients with paraproteinemia: a myeloma risk score developed in the region of the Comprehensive Cancer Center West].

    by C G Schaar, F Ong, S Snijder, P W Wijermans, P F Franck, J C Kluin-Nelemans

    Diagnoses in patients with paraproteinaemia are diverse; few (mostly single centre based) studies are known that describe incidence, diagnoses and follow-up in patients with paraproteinaemia. In the region of the Comprehensive Cancer Centre West in the Netherlands (population 1.6 million, 1992) a population-based registry was set up in the period 1991-1993. Patients (n = 1464; median age: 72 years; range: 16-102) were entered by clinical chemists, internists, haematologists, and pathologists. Multiple myeloma and plasmacytoma were diagnosed in 261 patients (18%), paraprotein-related haematological diseases in 159 patients (11%) and paraprotein-related internal diseases in 210 patients (14%). After bone marrow examination monoclonal gammopathy of unknown significance (MGUS) was diagnosed in 207 (14%) patients. No further diagnosis could be made in 627 (43%) patients mostly for lack of supplementary bone marrow and (or) X-ray examinations. Consequently, more than two-thirds of all patients with a newly found paraprotein did not show any sign of a haematological malignancy. Using these data a 'myeloma risk score' was developed to predict the presence of a multiple myeloma based on paraprotein type and concentration, aiding the physician in determining which patients should undergo further bone marrow and skeletal examinations.